Dosimetry-Guided [<sup>131</sup>I]MIBG Therapy in a Hemodialysis-Dependent Paraganglioma Patient.
Where this comes from
- Record sourced from PubMed, PMID 40610226.
- Also identified by DOI 10.2967/jnumed.125.269513.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
High specific-activity <sup>131</sup>I-metaiodobenzylguanidine ([<sup>131</sup>I]MIBG) therapy is approved for patients with pheochromocytoma or paraganglioma. As [<sup>131</sup>I]MIBG is not effectively cleared through dialysis, the 2008 European Association of Nuclear Medicine guidelines list renal insufficiency requiring dialysis as a contraindication for [<sup>131</sup>I]MIBG treatment. <b>Methods:</b> We describe the clinical and dosimetry findings of a hemodialysis-dependent patient with metastatic paraganglioma who was treated with [<sup>131</sup>I]MIBG. <b>Results:</b> The patient tolerated the treatment with acceptable radiation doses to normal organs and effective treatment doses. Radiation safety precautions were followed, and radiation exposures stayed below safe limits for staff. <b>Conclusion:</b> Dosimetry-guided treatment with [<sup>131</sup>I]MIBG in patients requiring hemodialysis is feasible. With appropriate dose reduction, the treatment can be effective with limited side effects.
Medical subject headings
- 3-Iodobenzylguanidine
- Paraganglioma
- Radiotherapy, Image-Guided
- Renal Dialysis